Tenax Therapeutics (TENX) Upgraded to Buy: Here's Why
Tenax Therapeutics: Q3 Earnings Snapshot
Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Tenax Therapeutics Q3 EPS $(0.31) Beats $(0.40) Estimate
Tenax Therapeutics (TENX) Stock Fair Value Falls After Cautious Analyst Calls On LEVEL Data
Tenax Therapeutics Temporarily Pauses Enrollment In LEVEL-2 Trial Of TNX-103 To Amend Criteria; Requests FDA Meeting
Tenax Therapeutics, Inc. (TENX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow
Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Guggenheim Downgrades Tenax Therapeutics to Neutral
Reported Earlier, Tenax Reports New Phase 3 Data Supporting TNX-103 In Pulmonary Hypertension Patients
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5
Tenax Therapeutics’ stock crashes on Phase III trial failure
Guggenheim Maintains Buy on Tenax Therapeutics, Lowers Price Target to $4
Evercore ISI Group Downgrades Tenax Therapeutics to In-Line, Lowers Price Target to $5
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients - Slideshow
William Blair Downgrades Tenax Therapeutics to Market Perform
Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.